X4 Pharmaceuticals (XFOR) Acquisitions (2019)
X4 Pharmaceuticals' (XFOR) quarterly Acquisitions came in at $52.8 million in Q4 2019, up 300.0% quarter-over-quarter from -$26.4 million in Q1 2019.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Acquisitions (2019) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Acquisitions for 1 consecutive years, with $52.8 million the latest figure, recorded in Q4 2019.
- For the quarter ending Q4 2019, Acquisitions changed N/A year-over-year to $52.8 million; the trailing twelve-month figure through Sep 2020 stood at $52.8 million (up 300.0% YoY), and the FY2019 full-year result was $26.4 million, changed N/A from the prior year.
- Acquisitions grew to $52.8 million in Q4 2019 per XFOR's latest filing, from -$26.4 million in the prior quarter.
- Across five years, Acquisitions topped out at $52.8 million in Q4 2019 and bottomed at -$26.4 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | -17.24 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | -23.00 Mn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | - |